Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verastem Inc (VSTM)
:VSTM
Holding VSTM?
Track your performance easily
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $14.22
Previous CloseN/A
Volume547.29K
Average Volume (3M)1.89M
Market Cap
$234.99M
Enterprise Value$69.54M
Total Cash (Recent Filing)$80.90M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Mar 18, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding44,506,527
10 Day Avg. Volume2,142,873
30 Day Avg. Volume1,885,615
Standard Deviation0.33
R-Squared0.00135
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.63
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue6.95
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$11.88Price Target Upside125.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Verastem News
Bulls Say, Bears Say
Bulls Say
Market PotentialThe total addressable market in LGSOC is large, with a $1.7 billion opportunity in the KRASm prevalent population and an additional $1.6 billion opportunity in the KRAS WT population.
Regulatory MilestoneThe FDA acceptance of the new drug application for the combination of avutometinib and defactinib for low-grade serous ovarian cancer is seen as a key milestone for Verastem Inc.
Stock PerformanceThe stock has shown strong momentum, with shares up approximately 50% since the recent price target upgrade, outperforming the XBI index.
Bears Say
Market ReactionVSTM shares experienced a significant drop due to the decision to initially seek approval only for KRAS-mutant patients, not including KRAS-wild-type patients.
Regulatory ChallengesVerastem Inc shares fell 20% due to market disappointment over a regulatory update limiting initial approval to a subset of patients.
Valuation ConcernsThe stock is still trading at near-cash levels with little value to a program that has the potential for an accelerated approval in 2025.
---
Ownership Overview
1.40% Insiders
5.89% Mutual Funds
43.24% Other Institutional Investors
41.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VSTM FAQ
What was Verastem Inc’s price range in the past 12 months?
Verastem Inc lowest stock price was $2.10 and its highest was $14.22 in the past 12 months.
What is Verastem Inc’s market cap?
Verastem Inc’s market cap is $234.99M.
When is Verastem Inc’s upcoming earnings report date?
Verastem Inc’s upcoming earnings report date is Mar 18, 2025 which is in 59 days.
How were Verastem Inc’s earnings last quarter?
Verastem Inc released its earnings results on Nov 06, 2024. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.738 by $0.138.
Is Verastem Inc overvalued?
According to Wall Street analysts Verastem Inc’s price is currently Undervalued.
Does Verastem Inc pay dividends?
Verastem Inc does not currently pay dividends.
What is Verastem Inc’s EPS estimate?
Verastem Inc’s EPS estimate is -0.83.
How many shares outstanding does Verastem Inc have?
Verastem Inc has 44,506,527 shares outstanding.
What happened to Verastem Inc’s price movement after its last earnings report?
Verastem Inc reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.738. Following the earnings report the stock price went down -6.977%.
Which hedge fund is a major shareholder of Verastem Inc?
Among the largest hedge funds holding Verastem Inc’s share is Viking Global Investors LP. It holds Verastem Inc’s shares valued at 0.
---
Verastem Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.88 (125.00% Upside)
$11.88 (125.00% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $56.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 63.8%
Last 30 Days ▲ 63.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.13%
12-Months-Change
Fundamentals
Return on Equity
-136.87%
Trailing 12-Months
Asset Growth
-28.26%
Trailing 12-Months
Company Description
Verastem Inc
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
---
VSTM Stock 12 Month Forecast
Average Price Target
$11.88
▲(125.00% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Moleculin Biotech
―
Cellectar Biosciences
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+4.78%
assigned a buy rating 12 days ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +4.78% per trade.
---